JP2009501224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009501224A5 JP2009501224A5 JP2008521436A JP2008521436A JP2009501224A5 JP 2009501224 A5 JP2009501224 A5 JP 2009501224A5 JP 2008521436 A JP2008521436 A JP 2008521436A JP 2008521436 A JP2008521436 A JP 2008521436A JP 2009501224 A5 JP2009501224 A5 JP 2009501224A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition
- formula
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 208000006011 Stroke Diseases 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 210000003169 central nervous system Anatomy 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 239000000460 chlorine Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 208000014674 injury Diseases 0.000 claims 7
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000009529 traumatic brain injury Effects 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 5
- 230000004112 neuroprotection Effects 0.000 claims 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 4
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 4
- 230000001537 neural effect Effects 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 208000028361 Penetrating Head injury Diseases 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 239000004090 neuroprotective agent Substances 0.000 claims 3
- 230000000324 neuroprotective effect Effects 0.000 claims 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 2
- 208000018652 Closed Head injury Diseases 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000002920 convulsive effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- -1 lamotigine Chemical compound 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000021657 Birth injury Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 claims 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 claims 1
- 208000014912 Central Nervous System Infections Diseases 0.000 claims 1
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 108010062745 Chloride Channels Proteins 0.000 claims 1
- 102000011045 Chloride Channels Human genes 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010058558 Hypoperfusion Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 108090000862 Ion Channels Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 claims 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 claims 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 206010038669 Respiratory arrest Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000002667 Subdural Hematoma Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 238000002585 cerebral angiography Methods 0.000 claims 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims 1
- 229960001403 clobazam Drugs 0.000 claims 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims 1
- 229960003120 clonazepam Drugs 0.000 claims 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 238000013171 endarterectomy Methods 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960002767 ethosuximide Drugs 0.000 claims 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims 1
- 229960003472 felbamate Drugs 0.000 claims 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 229960004002 levetiracetam Drugs 0.000 claims 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000003961 neuronal insult Effects 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960002695 phenobarbital Drugs 0.000 claims 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 229960002393 primidone Drugs 0.000 claims 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims 1
- 229960003312 retigabine Drugs 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 230000004799 sedative–hypnotic effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 229950004608 talampanel Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
- 230000004572 zinc-binding Effects 0.000 claims 1
- 229960002911 zonisamide Drugs 0.000 claims 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims 1
- GFZSXKJIDFDGFF-QMMMGPOBSA-N NC(OC[C@@H](c(cccc1)c1Cl)OC(N)=O)=O Chemical compound NC(OC[C@@H](c(cccc1)c1Cl)OC(N)=O)=O GFZSXKJIDFDGFF-QMMMGPOBSA-N 0.000 description 1
- LTHXJSUUZMYJSE-UHFFFAOYSA-N N[NH+]([O-])OCCc(cccc1)c1Cl Chemical compound N[NH+]([O-])OCCc(cccc1)c1Cl LTHXJSUUZMYJSE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69840305P | 2005-07-12 | 2005-07-12 | |
| PCT/US2006/026291 WO2007008562A2 (en) | 2005-07-12 | 2006-07-07 | Carbamate compounds for use in treating neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009501224A JP2009501224A (ja) | 2009-01-15 |
| JP2009501224A5 true JP2009501224A5 (https=) | 2009-06-18 |
Family
ID=37637734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008521436A Withdrawn JP2009501224A (ja) | 2005-07-12 | 2006-07-07 | 神経保護の方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20070021500A1 (https=) |
| EP (1) | EP1917009A2 (https=) |
| JP (1) | JP2009501224A (https=) |
| KR (1) | KR20080031951A (https=) |
| CN (1) | CN101287459A (https=) |
| AR (1) | AR054551A1 (https=) |
| AU (1) | AU2006269381A1 (https=) |
| BR (1) | BRPI0613006A2 (https=) |
| CA (1) | CA2615129A1 (https=) |
| CR (1) | CR9721A (https=) |
| EA (1) | EA200800294A1 (https=) |
| EC (1) | ECSP088179A (https=) |
| IL (1) | IL188729A0 (https=) |
| NI (1) | NI200800008A (https=) |
| NO (1) | NO20080738L (https=) |
| TW (1) | TW200800158A (https=) |
| WO (1) | WO2007008562A2 (https=) |
| ZA (1) | ZA200801401B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2385087T3 (es) * | 2005-07-26 | 2012-07-18 | Sk Biopharmaceuticals Co., Ltd | Procedimientos para tratar trastornos relacionados con sustancias |
| US9050005B2 (en) | 2005-08-25 | 2015-06-09 | Synapse Biomedical, Inc. | Method and apparatus for transgastric neurostimulation |
| WO2007103585A2 (en) * | 2006-03-09 | 2007-09-13 | Synapse Biomedical, Inc. | Ventilator assist system and method to improve respiratory function |
| US20080097153A1 (en) * | 2006-08-24 | 2008-04-24 | Ignagni Anthony R | Method and apparatus for grasping an abdominal wall |
| JP2010505856A (ja) * | 2006-10-06 | 2010-02-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | （ｓ）−（＋）−２−（２−クロロフェニル）−２−ヒドロキシ−エチルカルバメートの新規結晶 |
| US9079016B2 (en) * | 2007-02-05 | 2015-07-14 | Synapse Biomedical, Inc. | Removable intramuscular electrode |
| US9820671B2 (en) * | 2007-05-17 | 2017-11-21 | Synapse Biomedical, Inc. | Devices and methods for assessing motor point electromyogram as a biomarker |
| WO2009059033A1 (en) * | 2007-10-30 | 2009-05-07 | Synapse Biomedical, Inc. | Method of improving sleep disordered breathing |
| US8428726B2 (en) | 2007-10-30 | 2013-04-23 | Synapse Biomedical, Inc. | Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| KR101418061B1 (ko) * | 2012-09-28 | 2014-07-10 | 한국과학기술연구원 | 성상교세포의 글루타메이트 방출 기작 |
| CN105189451A (zh) | 2013-03-12 | 2015-12-23 | 比皮艾思药物研发有限公司 | 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| WO2017150903A1 (en) | 2016-02-29 | 2017-09-08 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds, processes for preparing them and their uses |
| US11471683B2 (en) | 2019-01-29 | 2022-10-18 | Synapse Biomedical, Inc. | Systems and methods for treating sleep apnea using neuromodulation |
| KR20230044274A (ko) * | 2020-08-31 | 2023-04-03 | (주)바이오팜솔루션즈 | 신경퇴행성 질환의 예방 또는 치료용 페닐 알킬 카바메이트 화합물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| HUP0203198A3 (en) * | 1999-08-20 | 2005-07-28 | Ortho Mcneil Pharm Inc | Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use |
| EP1383489B1 (en) * | 2001-02-27 | 2007-05-09 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| DK1809273T3 (da) * | 2004-09-16 | 2010-08-02 | Janssen Pharmaceutica Nv | Anvendelse af 2-phenyl-1,2-ethandiol-(di)carbamater til behandling af epileptogenese |
| PE20070325A1 (es) * | 2005-06-29 | 2007-05-12 | Alza Corp | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
-
2006
- 2006-07-06 US US11/481,601 patent/US20070021500A1/en not_active Abandoned
- 2006-07-07 WO PCT/US2006/026291 patent/WO2007008562A2/en not_active Ceased
- 2006-07-07 KR KR1020087003268A patent/KR20080031951A/ko not_active Withdrawn
- 2006-07-07 AU AU2006269381A patent/AU2006269381A1/en not_active Abandoned
- 2006-07-07 CN CNA2006800331046A patent/CN101287459A/zh active Pending
- 2006-07-07 EA EA200800294A patent/EA200800294A1/ru unknown
- 2006-07-07 CA CA002615129A patent/CA2615129A1/en not_active Abandoned
- 2006-07-07 BR BRPI0613006-2A patent/BRPI0613006A2/pt not_active IP Right Cessation
- 2006-07-07 JP JP2008521436A patent/JP2009501224A/ja not_active Withdrawn
- 2006-07-07 EP EP06786448A patent/EP1917009A2/en not_active Withdrawn
- 2006-07-11 TW TW095125161A patent/TW200800158A/zh unknown
- 2006-07-11 AR ARP060102977A patent/AR054551A1/es not_active Application Discontinuation
-
2008
- 2008-01-10 IL IL188729A patent/IL188729A0/en unknown
- 2008-01-11 NI NI200800008A patent/NI200800008A/es unknown
- 2008-02-11 ZA ZA200801401A patent/ZA200801401B/xx unknown
- 2008-02-11 NO NO20080738A patent/NO20080738L/no not_active Application Discontinuation
- 2008-02-11 CR CR9721A patent/CR9721A/es unknown
- 2008-02-12 EC EC2008008179A patent/ECSP088179A/es unknown
-
2009
- 2009-01-30 US US12/362,970 patent/US20090137652A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009501224A5 (https=) | ||
| JP6931019B2 (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| HRP20100304T1 (hr) | Uporaba 2-fenil-1,2-etanediol-(di)karbamata za liječenje epileptogeneze | |
| US20090137652A1 (en) | Methods for neuroprotection | |
| CA3016876C (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
| CA2439295C (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| JP2009501223A5 (https=) | ||
| JP2004523555A5 (https=) | ||
| JP2024028695A (ja) | 外傷性脳損傷を検出するための組成物および方法 | |
| US20070021501A1 (en) | Methods of treating epileptogenesis | |
| JP2017514884A (ja) | 医療用の（ｒ）−ピルリンドールおよびその薬学的に許容可能な塩 | |
| MX2007004491A (es) | Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos. | |
| US20070082873A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of schizophrenia | |
| JP2008184396A (ja) | 神経損傷に起因する身体機能障害の予防及び治療のための医薬 | |
| WO2025146469A1 (en) | Treatment for the symptoms of menopause and perimenopause | |
| WO2006020853A2 (en) | Pharmaceutical composition and method for treating neurodegenerative disorders | |
| US20080207631A1 (en) | Methods for the treatment and prevention of neurodegenerative conditions | |
| ZA200204682B (en) | Methods for the treatment and prevention of neurodegenerative conditions. | |
| WO2006020850A2 (en) | Pharmaceutical composition and method for treating neurodegenerative disorders | |
| JP2005531622A5 (https=) | ||
| WO2005049039A1 (en) | Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders |